AMPH vs PSA · P/E 12, rev $732.0M vs rev $4.82B
Amphastar P (AMPH) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Amphastar P (AMPH) is a drug manufacturers - specialty & generic company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported AMPH revenue for 2024-12-31 was $732.0M. Net income was $159.5M. Revenue was up 13.6% from 2023-12-31 to 2024-12-31. AMPH currently screens at market cap $880.1M and trailing P/E 12.0.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
AMPH currently screens at market cap $880.1M and trailing P/E 12.0. PSA currently screens at market cap $0.
Not investment advice. Open the AMPH and PSA stock pages for the full models.
Not investment advice.